Display options
Cite
Azzam G, Lanciano R, Arrigo S, et al. SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. Front Oncol. 2015;5:101doi: 10.3389/fonc.2015.00101.
Azzam, G., Lanciano, R., Arrigo, S., Lamond, J., Ding, W., Yang, J., Hanlon, A., Good, M., & Brady, L. (2015). SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. Frontiers in oncology, 5101. https://doi.org/10.3389/fonc.2015.00101
Azzam, Gregory, et al. "SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer." Frontiers in oncology vol. 5 (2015): 101. doi: https://doi.org/10.3389/fonc.2015.00101
Azzam G, Lanciano R, Arrigo S, Lamond J, Ding W, Yang J, Hanlon A, Good M, Brady L. SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. Front Oncol. 2015 May 05;5:101. doi: 10.3389/fonc.2015.00101. eCollection 2015. PMID: 26000249; PMCID: PMC4419680.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2015 May 05;5:101. doi: 10.3389/fonc.2015.00101. eCollection 2015.

SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer.

Frontiers in oncology

Gregory Azzam, Rachelle Lanciano, Steve Arrigo, John Lamond, William Ding, Jun Yang, Alexandra Hanlon, Michael Good, Luther Brady

Affiliations

  1. Department of Radiation Oncology, Drexel University College of Medicine , Philadelphia, PA , USA.
  2. Department of Radiation Oncology, Drexel University College of Medicine , Philadelphia, PA , USA ; Philadelphia CyberKnife Center, Delaware County Memorial Hospital , Havertown, PA , USA.
  3. Philadelphia CyberKnife Center, Delaware County Memorial Hospital , Havertown, PA , USA.
  4. Office of Nursing Research, School of Nursing, University of Pennsylvania , Philadelphia, PA , USA.

PMID: 26000249 PMCID: PMC4419680 DOI: 10.3389/fonc.2015.00101

Abstract

OBJECTIVE: Oligometastatic prostate cancer is a limited metastatic disease state in which potential long-term control is still possible with the use of targeted therapies such as surgery or stereotactic body radiation therapy (SBRT). SBRT may as well potentially prolong the time before the initiation of androgen deprivation therapy (ADT) and docetaxel chemotherapy for oligometastatic prostate cancer. The goal of this study is to outline prognostic factors associated with improved outcome with SBRT for metastatic prostate cancer and to quantify the effect of prior systemic treatments such as ADT and docetaxel on survival after SBRT.

METHODS: Twenty-four prostate cancer patients were treated with SBRT at the Philadelphia CyberKnife Center between August 2007 and April 2014. Retrospective data collection and analysis were performed for these patients on this Institutional Review Board approved study. Kaplan-Meier methodology was utilized to estimate and visually assess overall survival (OS) at the patient level, with comparisons accomplished using the log-rank test. Unadjusted hazard ratios were estimated using Cox proportional hazards regression modeling.

RESULTS: An improved median survival was noted for patients with oligometastatic disease defined as ≤4 lesions with median survival of >3 years compared with 11 months for polymetastases (p = 0.02). The use of docetaxel at some time in follow-up either before or after SBRT was associated with decreased survival with median survival of 9 months vs. >3 years (p = 0.01).

CONCLUSION: Prognosis was better for men with recurrent prostate cancer treated with SBRT if they had ≤4 metastases (oligometastases) or if docetaxel was not necessary for salvage treatment. The prolonged median OS for men with oligometastases in this population of heavily pretreated prostate cancer patients following SBRT may allow for improved quality of life because of a delay of more toxic salvage therapies.

Keywords: SBRT; androgen deprivation therapy; docetaxel; oligometastases; prostate cancer

References

  1. J Clin Oncol. 2013 Jun 1;31(16):2029-36 - PubMed
  2. J Clin Oncol. 2008 Jan 10;26(2):242-5 - PubMed
  3. Cancer. 2012 Jun 1;118(11):2962-70 - PubMed
  4. Front Oncol. 2013 Dec 03;3:293 - PubMed
  5. Nat Rev Clin Oncol. 2011 Jun;8(6):378-82 - PubMed
  6. Semin Radiat Oncol. 2008 Oct;18(4):215-22 - PubMed
  7. Cancer Radiother. 2014 Oct;18(5-6):524-34 - PubMed
  8. N Engl J Med. 2004 Oct 7;351(15):1513-20 - PubMed
  9. Clin Genitourin Cancer. 2013 Mar;11(1):27-32 - PubMed
  10. BMC Cancer. 2014 Sep 15;14:671 - PubMed
  11. Cancer. 2009 Jun 1;115(11):2388-99 - PubMed
  12. Urol Oncol. 2014 Jul;32(5):707-13 - PubMed
  13. Eur Urol. 2013 Aug;64(2):260-5 - PubMed
  14. Endocr Relat Cancer. 2014 Aug;21(4):T119-29 - PubMed
  15. Radiat Oncol. 2014 Jun 12;9:135 - PubMed
  16. J Clin Oncol. 1995 Jan;13(1):8-10 - PubMed

Publication Types